| SciPort RLP

2023 - 2040

Venetoclax in combination with the BTK inhibitor Ibrutinib and rituximab or conventional chemotherapy (bendamustine) and ibrutinib and rituximab in patients with treatment naïve Mantle Cell Lymphoma not eligible for high dose therapy - The European Mantle Cell Lymphoma Elderly III-Trial (#1281)

Univ.-Prof. Dr. GeorgHess

2023 - 2040

A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (#1417)

Dr. MariusFried

2023

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases - a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial

Dr. IreneSchmidtmann

2023 - 2026

ARTEMIS STUDYProspective, Multi-country, Comparative Observational Study (non-interventional) of clinical outcomes that benefit mHSPC patients treated with Apalutamide + ADT and Enzalutamide+ADT under routine clinical practice (ARTEMISpro)

PD Dr. MaximilianBrandt,
Dr. AnitaThomas

2023 - 2024

Mikrobiologische Performance Qualification der Robotersysteme APOTECAunit und APOTECAsyringe

Prof. Dr. IreneKrämer,
Dr. JudithThiesen,
DavidAckermann

2023 - 2027

Empowering treatment precision – Nutzung von Tumor-Organoiden zur Verbesserung des klinischen Managements von Kopf- und Halstumor-Patienten

Dr. DesireeGül,
Dr. AyaKhamis Hassan,
Prof. Dr. RolandStauber

2023 - 2026

TRR 355 A08

Prof. Dr. DanielaKramer

2023 - 2025

Topisch Psorias_2012

Prof. Dr. DanielaKramer

2023 - 2028

Epigenetics to treat Psoriasis

Prof. Dr. DanielaKramer

2023 - 2026

ReALiTy

Prof. Dr. DanielaKramer

Klinikum

FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz

Starten Sie Ihre Suche...

Klinikum

FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz